AstraZeneca deepens China presence with FibroGen deal
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...
M&A News: AstraZeneca Expands China Footprint With FibroGen Deal
AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.
AZN Lawsuit Alert! Class Action Against AstraZeneca Plc.
A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...
AstraZeneca to buy FibroGen's China unit for $160 million
AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...
AstraZeneca PLC ADR rises Thursday, outperforms market
AstraZeneca PLC ADR closed 14.96% below its 52-week high of $87.68, which the company achieved on August 30th.
Reuters2 天
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...
AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.
AstraZeneca PLC ADR outperforms competitors on strong trading day
AstraZeneca PLC ADR closed 14.68% short of its 52-week high of $87.68, which the company achieved on August 30th.
pharmaphorum3 天
A history of AstraZeneca
AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...